About Allergic Rhinitis Drugs
Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases.
Technavios analysts forecast the global allergic rhinitis market to grow at a CAGR of 0.95% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global allergic rhinitis drugs market for the period 2016-2020. To calculate the market size, it considers revenue generated from the sales of prescription and off-label drugs used to treat allergic rhinitis.
The market is divided into the following segments based on geography:
Americas
APAC
Europe
Technavios report, Global Allergic Rhinitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
AstraZeneca
GlaxoSmithKline
Meda Pharmaceuticals
Merck
Sanofi
UCB
Other prominent vendors
Adamis Pharmaceuticals
Alcon
Alergo Pharma
ALK-Abelló
Allergy Therapeutics
Almirall
Ampio
Anergis
Apotex
Ares Life Sciences
Array BioPharma
Aspen Pharmacare
Atopix Therapeutics
Barr Laboratories
Belcher Pharmaceuticals
Circassia Pharmaceuticals
Dainippon Sumitomo
DBV Technologies
Dr Reddys Laboratories
Eddingpharm
Genentech
Greer Laboratories
Hanmi Pharmaceuticals
Hisamitsu Pharmaceutical
Intas Pharmaceuticals
Kyowa Hakko
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
Mylan
Nektar Therapeutics
Novartis
Nuvo Research
Nycomed
Omega Pharma
Ono Pharmaceuticals
Pfizer
Revance Therapeutics
Roxane Laboratories (Boehringer Ingelheim)
Shionogi
Stallergenes
Sun Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceuticals
Verona Pharma
VentiRx Pharmaceuticals
Market driver
Increased prevalence of allergic rhinitis
For a full, detailed list, view our report
Market challenge
Patent expiries and competition from generic drugs
For a full, detailed list, view our report
Market trend
Increased R&D
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview: Allergic rhinitis
Understanding the disease
Classification of allergic rhinitis
Causes
Signs and symptoms
Risk factors
Diagnosis and testing
Treatment
Epidemiology
Economic burden and impact on quality of life
PART 06: Pipeline analysis
Information on pipeline candidates
Clinical trial information of allergic rhinitis
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation based on class of drugs
Antihistamines
Intranasal corticosteroids
Immunotherapies
Global antihistamines drugs market
Global intranasal corticosteroids drugs market
Global immunotherapies drugs market
PART 09: Market segmentation by route of administration
Oral
Parenteral
Intranasal
PART 10: Market segmentation by dosage form
Solid
Liquid
PART 11: Geographical segmentation
Global allergic rhinitis drugs market by geography 2015-2020
Allergic rhinitis drugs market in Americas
Allergic rhinitis drugs market in EMEA
Allergic rhinitis drugs market in APAC
PART 12: Market drivers
Increased prevalence of allergic rhinitis
Rise in awareness about allergic rhinitis
High usage of tobacco
Presence of high unmet medical needs
PART 13: Impact of drivers
PART 14: Market challenges
Increased preference for CAM
Patent expiries and competition from generic drugs
Adverse effects of drugs
Poor patient adherence
PART 15: Impact of drivers and challenges
PART 16: Market trends
Self-medication using OTC products
Increased R&D
Intense competition
Strategic alliances
PART 17: Vendor landscape
Competitive scenario
Market share analysis 2015
AstraZeneca
GlaxoSmithKline
Meda Pharmaceuticals
Merck
Sanofi
UCB
Other prominent vendors
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of allergic rhinitis
Exhibit 03: Risk factors associated with allergic rhinitis
Exhibit 04: Major diagnostic procedures for allergic rhinitis
Exhibit 05: Imaging studies used to diagnose and evaluate allergic rhinitis
Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
Exhibit 07: Non-pharmacological therapies for allergic rhinitis
Exhibit 08: Examples of non-pharmacological therapies
Exhibit 09: Treatment algorithm of allergic rhinitis
Exhibit 10: Prevalence of allergic rhinitis in China
Exhibit 11: Global allergic rhinitis drugs market: Pipeline portfolio
Exhibit 12: Allergic rhinitis clinical trials by development phase 2015
Exhibit 13: Allergic rhinitis clinical trials by trial status 2015
Exhibit 14: Global allergic rhinitis drugs market 2015-2020 ($ billions)
Exhibit 15: Five forces analysis
Exhibit 16: Global allergic rhinitis market based on class of drugs
Exhibit 17: Examples of prescription and OTC intranasal corticosteroids
Exhibit 18: Global allergic rhinitis drugs market based on class of drugs 2015
Exhibit 19: Global allergic rhinitis drugs market based on class of drugs 2015-2020 ($ billions)
Exhibit 20: Global antihistamines drugs market 2015-2020 ($ billions)
Exhibit 21: Global intranasal corticosteroids drugs market 2015-2020 ($ billions)
Exhibit 22: Global immunotherapies drugs market 2015-2020 ($ billions)
Exhibit 23: Global allergic rhinitis drugs market by route of administration
Exhibit 24: Global allergic rhinitis drugs market segmentation by dosage form
Exhibit 25: Global allergic rhinitis drugs market by geography 2015
Exhibit 26: Global allergic rhinitis drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 27: Allergic rhinitis drugs market in Americas 2015-2020 ($ billions)
Exhibit 28: Allergic rhinitis drugs market in EMEA 2015-2020 ($ billions)
Exhibit 29: Allergic rhinitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 30: Drivers of global allergic rhinitis drugs market
Exhibit 31: Impact of drivers
Exhibit 32: Challenges of global allergic rhinitis drugs market
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Trends of global allergic rhinitis drugs market
Exhibit 35: Drugs that underwent Rx-to-OTC switch in the US
Exhibit 36: Global allergic rhinitis drugs market vendor share analysis 2015
Exhibit 37: YoY revenue comparison of top drugs for allergic rhinitis 2012-2014 ($ billions)
Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 41: AstraZeneca: Key takeaways
Exhibit 42: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 43: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 45: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
Exhibit 46: GlaxoSmithKline: Key takeaways
Exhibit 47: Meda Pharmaceuticals: Product segmentation by revenue 2014
Exhibit 48: Meda Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 49: Meda Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 50: Meda Pharmaceuticals: Top-selling drugs
Exhibit 51: Meda Pharmaceuticals: YoY growth and revenue of Dymista 2012-2014 ($ millions)
Exhibit 52: Meda Pharmaceuticals: YoY growth and revenue of EpiPen 2012-2014 ($ millions)
Exhibit 53: Meda Pharmaceuticals: Key takeaways
Exhibit 54: Merck: Business segmentation by revenue 2014
Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 56: Merck: Geographical segmentation by revenue 2014
Exhibit 57: Merck: Top-selling drugs
Exhibit 58: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)
Exhibit 59: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)
Exhibit 60: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)
Exhibit 61: Merck: Key takeaways
Exhibit 62: Sanofi: Business segmentation by revenue 2014
Exhibit 63: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 64: Sanofi: Geographical segmentation by revenue 2014
Exhibit 65: Sanofi: Top-selling drugs
Exhibit 66: Sanofi: YoY growth and revenue of Allegra 2012-2014 ($ millions)
Exhibit 67: Sanofi: YoY growth and revenue of Allegra OTC 2012-2014 ($ millions)
Exhibit 68: Sanofi: YoY revenue comparison of Nasacort ($ millions)
Exhibit 69: Sanofi: Key takeaways
Exhibit 70: UCB: Product segmentation by revenue 2014
Exhibit 71: UCB: Product segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 72: UCB: Geographical segmentation by revenue 2014
Exhibit 73: UCB: YoY growth and revenue of Zyrtec 2012-2014 ($ millions)
Exhibit 74: UCB: YoY growth and revenue of Xyzal 2012-2014 ($ millions)
Exhibit 75: UCB: Key takeaways
